| Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy JA Davis, DW Sborov, W Wesson, K Julian, AO Abdallah, JP McGuirk, ... Transplantation and Cellular Therapy 29 (9), 567-571, 2023 | 28 | 2023 |
| Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review W Wesson, VL Galate, DW Sborov, B McClune, AM Goodman, B Gyawali, ... European Journal of Cancer 167, 152-160, 2022 | 12 | 2022 |
| Patient characteristics and outcomes of outpatient tisagenlecleucel recipients for B cell non-Hodgkin lymphoma N Ahmed, W Wesson, MU Mushtaq, DL Porter, SD Nasta, J Brower, ... Transplantation and cellular therapy 29 (7), 449. e1-449. e7, 2023 | 9 | 2023 |
| Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma W Wesson, D Dima, N Suleman, MSI Saif, C Tabak, E Logan, JA Davis, ... Transplantation and Cellular Therapy 30 (9), 876-884, 2024 | 8 | 2024 |
| Safety and efficacy of eltrombopag in patients with post‐CAR T cytopenias W Wesson, N Ahmed, A Rashid, C Tabak, E Logan, J Marchena‐Burgos, ... European Journal of Haematology 112 (4), 538-546, 2024 | 7 | 2024 |
| “Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy N Ahmed, W Wesson, MU Mushtaq, R Bansal, H AbdelHakim, S Bromert, ... Frontiers in Oncology 13, 1206715, 2023 | 6 | 2023 |
| Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed car T-cell therapy. Transpl Cell Ther. 2023; 29: 567-71 JA Davis, DW Sborov, W Wesson, K Julian, AO Abdallah, JP McGuirk Table, 0 | 6 | |
| Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020 O Van Oekelen, N Birrer, W Wesson, VL Galate, ERS Cliff, AM Goodman, ... Blood Cancer Journal 12 (11), 155, 2022 | 4 | 2022 |
| Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel N Ahmed, W Wesson, F Lutfi, DL Porter, V Bachanova, LJ Nastoupil, ... Blood Advances 8 (20), 5346-5354, 2024 | 3 | 2024 |
| Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: a multicenter analysis A Alsouqi, G Ahmed, J Wang, G Cassanello, A Szabo, AE Rojek, ... American journal of hematology 99 (8), 1624-1627, 2024 | 3 | 2024 |
| Characterizing clinical trials for CAR T targeting solid tumors from 2018 to 2023: A systematic review. W Wesson, FS Ayoobkhan, Z Mahmoudjafari, MU Mushtaq, AOA Abdallah, ... Journal of Clinical Oncology 42 (16_suppl), e15080-e15080, 2024 | 3 | 2024 |
| A multicenter experience: duration of mandatory CRS and ICANS monitoring for myeloma and lymphoma CAR-T recipients W Wesson, D Dima, J Davis, A Rashid, F Furqan, MSI Saif, E Logan, ... Transplantation and Cellular Therapy 30 (2), S207-S208, 2024 | 3 | 2024 |
| Balancing monitoring and access: optimal duration of monitoring for CD19 and BCMA CART recipients for lymphoma and myeloma W Wesson, A Rashid, MSI Saif, E Logan, C Tabak, M McGann, JA Davis, ... Blood 142, 6914, 2023 | 3 | 2023 |
| Chimeric Antigen Receptor T-Cell (CAR-T) Access Among Rural and Health Professional Shortage Area (HPSA) Populations in the Midwest C Tabak, A Rashid, S Pepper, W Wesson, AO Abdallah, F Lutfi, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | 2 | 2024 |
| Chimeric Antigen Receptor T-Cell (CAR-T) therapy in secondary central nervous system large B-Cell Lymphoma (SCNSL): A multicenter retrospective analysis G Ahmed, A Alsouqi, A Szabo, AE Rojek, PA Riedell, FT Awan, L Samples, ... Blood 142, 3088, 2023 | 2 | 2023 |
| Eltrombopag stimulation for neutrophil and platelet recovery following axicabtagene ciloleucel (axi-cel) therapy in lymphoma W Wesson, M Nelson, M Mushtaq, R Bansal, R Kribs, AK Singh, ... Blood 140 (Supplement 1), 12757-12759, 2022 | 2 | 2022 |
| Neurocognitive testing to predict ICANS post-CAR T. W Wesson, L Scott, N Suleman, S DeJarnette, AOA Abdallah, FU Lutfi, ... Journal of Clinical Oncology 42 (16_suppl), e19003-e19003, 2024 | 1 | 2024 |
| BCMA Re-Emergence: Can It Serve As a Prognostic Biomarker in Multiple Myeloma after CAR-T? A Rashid, W Wesson, C Tabak, F Lutfi, MU Mushtaq, JP McGuirk, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | 1 | 2024 |
| Defining the optimal Post-CART monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel: a cell therapy consortium study W Wesson, PA Riedell, DL Porter, F Lutfi, V Bachanova, LJ Nastoupil, ... Transplantation and Cellular Therapy 30 (2), S206-S207, 2024 | 1 | 2024 |
| Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure F Lutfi, B Ansari, A Hawa, AO Abdallah, Z Shah, M Hoffmann, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | 1 | 2024 |
